NEW YORK (Reuters Health)—Gene expression and chromatin accessibility can be used to identify two Crohn’s disease (CD) molecular subclasses that match distinct disease phenotypes, researchers report. “The hope one day is to be able to test Crohn’s patients for the subtype of the disease they have, and thus determine which treatment should work best,” Dr….
Articles by Natasha Yetman
Docs Still Order Imaging for Low Back Pain, Against Recommendations
(Reuters Health)—Many doctors who order computed tomography (CT) or magnetic resonance imaging (MRI) scans for patients with low back pain do so fearing that patients will be upset if they do not get imaging and because there is too little time to explain the risks and benefits of the tests, a new study found. The…
Liposomal Bupivacaine Helpful in Total Knee Arthroplasty
NEW YORK (Reuters Health)—Local infiltration of liposomal bupivacaine in patients undergoing total knee arthroplasty (TKA) curbed use of opioids and antiemetics and appeared to be both beneficial and cost effective in a recent study. As Dr. Bryan Sakamoto told Reuters Health by email, the results “suggest that liposomal bupivacaine is effective as part of a…
Tenet Healthcare to Pay More Than $513 Million in Fraud Scheme
WASHINGTON (Reuters)—U.S. hospital chain Tenet Healthcare Corp. and two of its Atlanta-area units will pay more than $513 million to resolve criminal charges and civil claims relating to a scheme to defraud the U.S. and pay kickbacks in exchange for patient referrals, the U.S. Department of Justice said on Monday.1 Tenet had disclosed in August…
Big Pharma vs. Big Pharma in Court Battles over Biosimilar Drugs
ZURICH (Reuters)—The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines. These drug makers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars—biopharmaceutical drugs with the treatment properties of medicines…
Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD
NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…
Do RA Patients in Clinical Trials for Biologics Represent the Average?
It’s estimated that a majority of patients with rheumatoid arthritis (RA) have been exposed to biologic treatments. However, the randomized controlled trials demonstrating the safety and efficacy of these biologic agents have strict participant eligibility requirements. New research has examined the requirements of 30 trials for biologics and applied those standards to two large clinical cohorts. The result: A majority of these RA patients did not satisfy the criteria…
FDA Approves Ustekinumab for Crohn’s Disease
(Reuters)—Johnson & Johnson says on Monday that the U.S. Food and Drug Administration approved the company’s psoriasis drug, ustekinumab (Stelara), for use in adults with Crohn’s disease. The drug is approved in the U.S. to treat plaque psoriasis and a type of arthritis associated with psoriasis. Crohn’s is a chronic inflammatory condition in the gastrointestinal…
FDA Approves Adalimumab-atto, a Biosimilar of Humira
WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira). The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions. Amjevita is the fourth biosimilar to be approved…
Novel Astrocytic Autoantibody Associated with Relapsing Meningoencephalomyelitis
NEW YORK (Reuters Health)—An autoantibody to glial fibrillary acidic protein (GFAP) is associated with relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapy, researchers report. “Autoimmune GFAP meningoencephalomyelitis is the second autoimmune neurological disease in which the target of the immune attack is recognized to be the astrocyte type of brain cell,” Dr. Vanda A. Lennon…
- « Previous Page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- …
- 97
- Next Page »